Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Immunoblastic Lymphadenopathy 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1Breast Neoplasms 1

Interventions

Doxorubicin 8Cyclophosphamide 8Vincristine 7Prednisone 7Etoposide 6Brentuximab Vedotin 4prednylidene 3etoposide phosphate 3Bortezomib 3pembrolizumab 2deltacortene 2Vorinostat 2Prednisolone 2Ifosfamide 2tazemetostat 1romidepsin 1pirarubicin 1duvelisib 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Nivolumab 1Methylprednisolone 1Methotrexate 1Melphalan 1Lenalidomide 1Lactones 1Gemcitabine 1Everolimus 1Diet, Gluten-Free 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Enteropathy-Associated T-Cell Lymphoma × Lactones × Clear all
NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Completed
22 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡